[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623414":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":18,"armGroups":25,"interventions":34,"overallOfficials":54,"centralContacts":59,"locations":64,"responsibleParty":79,"collaborators":18,"id":81,"slug":18,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":18,"enrollmentInfo":90,"targetDuration":18,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":18,"overallStatus":66,"whyStopped":18,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"RenJi Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of patients with pCR","Number of patients with pathological complete response\u002FNumber of all eligible patients","1-2 weeks after surgery",[14],{"measure":15,"description":16,"timeFrame":17},"Proportion of patients with adverse events","Number of patients with adverse events during neoadjuvant therapy assessed according to the NCI CTCAE v5.0\u002FNumber of all eligible patients","From the date of starting neoadjuvant therapy to the end of the treatment (up to approximately 1 year)",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"NA","SINGLE_GROUP","TREATMENT",{"masking":24,"maskingDescription":18,"whoMasked":18},"NONE",[26],{"label":27,"type":28,"description":29,"interventionNames":30},"neoadjuvant Iparomlimab and Tuvonralimab (QL1706)","EXPERIMENTAL","Iparomlimab and Tuvonralimab (QL1706) in combination with weekly paclitaxel and carboplatin as neoadjuvant therapy",[31,32,33],"Drug: Iparomlimab and Tuvonralimab","Drug: Paclitaxel","Drug: Carboplatin",[35,42,48],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"DRUG","Iparomlimab and Tuvonralimab","5.0mg\u002Fkg qw, start from C1D15",[27],[41],"QL1706",{"type":36,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"Paclitaxel","80mg\u002Fm\\^2 qw",[27],[47],"PTX",{"type":36,"name":49,"description":50,"armGroupLabels":51,"otherNames":52},"Carboplatin","AUC=1.5, D1, 8, 15, every 28 days",[27],[53],"CBP",[55],{"name":56,"affiliation":57,"role":58},"Wenjin Yin","Renji Hospital, School of Medicine, Shanghai Jiaotong University","PRINCIPAL_INVESTIGATOR",[60],{"name":56,"role":61,"phone":62,"phoneExt":18,"email":63},"CONTACT","86(21)68385569","yinwenjin@renji.com",[65],{"facility":57,"status":66,"city":67,"state":18,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"RECRUITING","Shanghai","200127","China","CN",{"type":72,"coordinates":73},"Point",[74,75],121.45806,31.22222,{"lat":75,"lon":74},[78],{"name":56,"role":61,"phone":62,"phoneExt":18,"email":63},{"type":58,"investigatorFullName":56,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Deputy Chief of Breast Surgery Department","100623414",false,"NCT07396324","Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer","NEOadjuvant Iparomlimab and Tuvonralimab (QL1706) Plus Chemotherapy in Patients With Hormone Receptor Positive And HER2-Negative Breast Cancer: a Prospective, Single Arm, Multicenter Clinical Trial","NEO-ITHRAN","Inclusion Criteria:\n\n* Aged ≥18 years\n* Histologically confirmed hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer\n* Subjects with at least one evaluable lesion\n* ECOG 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV)\n* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period","ALL","18 Years",{"count":91,"type":92},55,"ESTIMATED","INTERVENTIONAL",[95],"PHASE2","This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative breast cancer.",[98],"HR-positive\u002FHER2-negative Breast Cancer","2026-05-10",{"date":101,"type":102},"2026-05-13","ACTUAL",{"date":104,"type":102},"2026-05-01",{"date":106,"type":92},"2031-12",{"name":5,"class":6},1]